Immunotherapy before surgery for certain colorectal cancers
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have stage II or III colorectal cancer (spread to nearby tissue but not distant organs)
- Your tumor has a specific DNA repair problem (called dMMR or MSI-High), confirmed by testing
- You are healthy enough for surgery (no other serious health problems that would make surgery risky)
- You do not have an active autoimmune disease, active infection, or inflammatory bowel disease
- You are not allergic to tislelizumab or similar immunotherapy drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This study tests whether an immunotherapy drug called tislelizumab can help prevent colon cancer from coming back after surgery. It is for people with a specific genetic feature (dMMR) in their tumor, which may make the treatment more effective.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Colo-rectal Cancer (dMMR/MSI-H CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.